SUPNHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. hold a median 12-month price target of $63 — +36.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Supernus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (38): The company has been issuing shares or taking on financing, diluting existing holders.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SUPN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +36.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 9 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $63 → $67 |
| 19 Dec 2025 | Stifel | Maintains | Hold | — |
| 29 Oct 2025 | B of A Securities | Initiates | Buy | — |
| 23 Oct 2025 | TD Cowen | Maintains | Buy | — |
| 9 Oct 2025 | Piper Sandler | Upgrade | Overweight | — |
| 30 Sept 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 29 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 6 Aug 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 26 Feb 2025 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 19 Feb 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 11 Sept 2024 | Piper Sandler | Downgrade | Neutral | — |
| 28 Feb 2024 | Piper Sandler | Maintains | Overweight | — |
| 9 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 25 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 10 May 2023 | Piper Sandler | Maintains | Overweight | — |
| 23 Jan 2023 | Piper Sandler | Maintains | Overweight | — |
| 31 Aug 2022 | Piper Sandler | Maintains | Overweight | — |
| 13 Apr 2021 | Jefferies | Upgrade | Buy | — |
| 16 June 2020 | Piper Sandler | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SUPN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 39% of US stocks
Cheaper than 38% of US stocks
Cheaper than 14% of US stocks
Higher than 80% of US stocks
Higher than 68% of US stocks
Higher than 93% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 35% of US stocks
Higher than 45% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Supernus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Indivior has proposed a merger with Supernus that could broaden its central nervous system portfolio, cut costs, and reduce its reliance on Sublocade, though the deal's closing remains uncertain.
Why it matters — For Supernus watchers, the proposed merger signals a potential expansion of its CNS portfolio and cost synergies, though completion is not yet assured.
Zacks Investment Research published an article comparing Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries (TEVA), examining which of the two Medical-Generic Drugs stocks is more attractive to value investors.
Why it matters — The article signals that SUPN is being evaluated alongside a major industry peer on value-investment criteria, which could influence investor perception of the stock.
Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti Jr., is investigating the proposed acquisition of Supernus Pharmaceuticals by Indivior, under which Supernus shareholders would receive 1.5401 Indivior shares per Supernus share. The firm is examining the adequacy of the price and the process of the proposed deal.
Why it matters — A SUPN watcher would care because the law firm is investigating whether the price and process of the proposed sale to Indivior are fair to Supernus shareholders.
Supernus Pharmaceuticals (SUPN) was added to the Zacks Rank #1 (Strong Buy) List on August 7th, 2026.
Why it matters — A Strong Buy designation by Zacks Investment Research signals that the stock is viewed favorably by the research firm's quantitative ranking system.
Supernus Pharmaceuticals (SUPN) was included in Zacks Investment Research's Zacks Rank #1 (Strong Buy) value stocks list for August 7th, 2026, alongside BCAL and NXRT.
Why it matters — A SUPN watcher would care because the company was singled out by Zacks as a top-ranked value stock, a notable recognition of its standing.
The 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. have a median 12-month price target of $63, with estimates ranging from $55 to $67. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Supernus Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Supernus Pharmaceuticals, Inc. 84 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Supernus Pharmaceuticals, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +36.3% from the last close, and Ticker Nerd's factor model ranks Supernus Pharmaceuticals, Inc. 84 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Supernus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SUPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $67 over the next 12 months.
Supernus Pharmaceuticals, Inc. returned +5.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026". Indivior has proposed a merger with Supernus that could broaden its central nervous system portfolio, cut costs, and reduce its reliance on Sublocade, though the deal's closing remains uncertain.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its primary function is to innovate therapeutic solutions that address unmet medical needs in neurology and psychiatry. Known for its robust research and development efforts, Supernus has a portfolio that includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), and bipolar disorder. The company's significant contributions to the CNS field have made it a notable entity in the pharmaceutical industry. Supernus operates through a combination of proprietary products and strategic partnerships, ensuring a steady pipeline of new medications. This focus on CNS disorders highlights its specialization within healthcare, impacting patient lives by improving management and treatment of these conditions. Supernus Pharmaceuticals' market significance is underscored by its dedication to enhancing the quality of life for patients through advanced, targeted therapies. By leveraging extensive research, clinical trials, and regulatory expertise, Supernus continues to play an important role in the pharmaceutical sector's innovation landscape.
CEO Mr. Jack A. Khattar M.B.A. · 674 employees · United States · https://www.supernus.com